Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Organon & Co.

Barclays analyst Tim Long maintained a Hold rating on Logitech today and set a price target of $101.00. According to TipRanks, Long is a 5-star ana...

Barclays Sticks to Its Hold Rating for Logitech (LOGI)

Origin Enterprises plc ( ($GB:OGN) ) has provided an announcement. Origin Enterprises plc has disclosed a transaction involving a person closely as...

Origin Enterprises Reports Small Share Purchase by Associate of Non-Executive Director

Organon ( ($OGN) ) has shared an update. On July 23, 2026, Organon held a virtual special meeting of stockholders to vote on a proposed merger unde...

Organon Shareholders Approve Merger with Sun Pharma

Organon ( ($OGN) ) has issued an announcement. On April 26, 2026, Organon agreed to be acquired through a merger in which it will become a wholly o...

Organon Issues Supplemental Disclosures on Sun Pharma Merger

The latest announcement is out from Origin Enterprises plc ( ($GB:OGN) ). Origin Enterprises plc has reissued 65,791 treasury shares to satisfy the...

Origin Enterprises Reissues Treasury Shares for UK Employee Options

Morgan Stanley analyst Erik Woodring maintained a Sell rating on Logitech today and set a price target of $88.00. Woodring covers the Technology se...

Morgan Stanley Remains a Sell on Logitech (LOGI)

Origin Enterprises plc ( ($GB:OGN) ) has shared an update. Origin Enterprises plc has reissued a small number of treasury shares to satisfy the exe...

Origin Enterprises Reissues Treasury Shares for Long-Term Incentive Plan

Origin Enterprises plc ( ($GB:OGN) ) just unveiled an update. Origin Enterprises plc has transferred 52,044 treasury shares to meet obligations und...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OGN	$13.55	+0.22%	1.99M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OGN	$13.55	+0.2%	1.99M
3
4
5
6

OGN

OGN

Get Organon & Co. Data in Excel

Get Organon & Co. Data in Excel